Sandoz Group AG (SDZNY) is a global leader in the development, manufacturing, and marketing of biosimilars and generic pharmaceuticals. The company focuses on providing high-quality, affordable medicines to patients worldwide, with a strong emphasis on innovation and sustainability. Sandoz's offerings include a diverse portfolio of biosimilars and generics that address a wide range of therapeutic areas.
-
Biosimilars - Develops and markets biologic medicines that are similar to existing reference products, driving growth through new launches and strong demand. Key products include:
- Omnitrope - The world's first biosimilar, holding a 37% market share in the somatropin market.
- Hyrimoz - A biosimilar adalimumab with close to an 80% market share in the U.S. biosimilar adalimumab market.
- Tyruko - Targets the multiple sclerosis market with growing adoption in Europe.
- Pyzchiva - A leading biosimilar in Europe launched in 2024.
- Wyost/Jubbonti - A biosimilar denosumab launched in Canada, with U.S. launch plans.
- Enzeevu - A biosimilar aflibercept approved by the FDA, enhancing the ophthalmology portfolio.
-
Generics - Manufactures and sells a wide range of generic pharmaceuticals, providing a stable foundation for the business and benefiting from favorable pricing dynamics and recent launches across Europe.
You might also like
Research analysts covering SANDOZ GROUP.
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Cimerli | 2024 | The acquisition contributed significantly to the strong performance of the biosimilar business, particularly in North America, driving growth in the third quarter and the first nine months of 2024. However, no specific details regarding the deal value or structure were provided |
No recent press releases or 8-K filings found for SDZNY.